Maravai LifeSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Initiates 2021 Financial Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Maravai LifeSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Initiates 2021 Financial Guidance

Maravai LifeSciences (MRVI) Tops Q4 EPS by 2c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

March 2, 2021 4:20 PM EST

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $98.4 million versus the consensus estimate of $89.02 million.

Highlights include:

Revenue of $98.4 million for the fourth quarter and $284.1 million for the full year of 2020, representing 173.5% and 98.5% increases, respectively, over the corresponding periods of 2019;Expanded our IP Portfolio with a third U.S. patent granted for CleanCap® technology for the co-transcriptional capping of messenger RNA (mRNA); Expanded nucleic acid production capacity via infrastructure investment and manufacturing process improvements, including substantial... More